Brought to you by 
J&J buying Scios for $2.69bn cash
19 Feb 2003
Executive Summary
Johnson & Johnson has agreed to acquire Scios Inc. (public biotech; cardiovascular and autoimmune therapeutics) for $2.69bn (or $2.4bn, net of Scios's cash). Scios stockowners will receive $45 for each common share they hold, a 35% premium to the market average in the period before the negotiations were first rumored.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com